Yantai Dongcheng Biochemicals Co., Ltd. Class A
SSZSE:00267513.40
CNY
+0.27
(+2.06%)
ISIN
CNE100001DP5
Return %
Stock
S&P 500
1Y
-7.27
13.14
3Y
-20.33
80.78
5Y
-6.29
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhi Gang Luo
- Full Time Employees
- 2,583
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No.7 Changbaishan Road Yantai SD China 264006
- IPO Date
- May 14, 2012
- Website
- dcb-group.com
- Similar Companies
- Business
- Yantai Dongcheng Pharmaceutical Group Co., Ltd. operates as a comprehensive pharmaceutical company primarily engaged in the manufacture and sale of biochemical active pharmaceutical ingredients (APIs), chemical medicines, proprietary Chinese medicines, and nuclide drugs. Its core product portfolio includes biochemical APIs such as Heparin Sodium, Chondroitin Sulphate, Cytochrome C, Hyaluronic Acid, Collagen, and Glucosamine, all compliant with major global pharmacopoeias including the European Pharmacopoeia, Japanese Pharmacopoeia, and United States Pharmacopeia. The group also produces various dosage forms of pharmaceuticals including powder injections, tablets, and capsules across therapeutic areas such as cardiovascular, oncology, urology, and orthopedics. The company has developed a leading position in China's nuclide drug sector, covering the entire industry chain from diagnostic to therapeutic nuclide drugs. In recent years, Yantai Dongcheng has strategically expanded through acquisitions of domestic nuclide drug enterprises and has pursued a global expansion strategy prioritizing partnerships with distributors in Europe and Southeast Asia to enter new international markets. In 2024 and 2025, the company made significant advancements including the clinical trial approval for a prostate cancer treatment drug by its subsidiary and initiated the spin-off and Hong Kong Stock Exchange listing of its biotechnology subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. Yantai Dongcheng has also strengthened its research and development efforts, targeting substantial investment in innovation with a broad pipeline of over 50 patented drugs focusing on oncology and chronic diseases. Furthermore, the company maintains critical regulatory certifications such as U.S. FDA site audit approval and European CEP certificates, supporting its robust international export activities spanning more than 50 countries. Founded in 1995 and headquartered in Yantai, Shandong Province, China, Yantai Dongcheng Pharmaceutical Group remains committed to rigorous quality assurance, regulatory compliance, and supply chain management. The group actively collaborates within industry consortia to promote innovation and efficiency and has implemented cross-departmental project management systems to bolster operational performance. Recent corporate developments include supplementary shareholder agreements to support subsidiary guarantees and ongoing clinical trial advancements. With a comprehensive product lineup and strategic initiatives to enhance global market presence, Yantai Dongcheng Pharmaceutical Group continues to consolidate its standing as a leading pharmaceutical manufacturer and innovator in China and beyond.